Wolfe Research analyst Andy Chen downgraded Vertex Pharmaceuticals (VRTX) to Peer Perform from Outperform.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $621 from $617 at Goldman Sachs
- Vertex Pharmaceuticals price target lowered to $442 from $450 at Scotiabank
- Vertex Pharmaceuticals price target raised to $464 from $462 at Morgan Stanley
- Optimistic Outlook for Vertex Pharmaceuticals Driven by Strong Market Penetration and Strategic Clinical Advancements
- Cautious Hold Rating for Vertex Pharmaceuticals Amid Mixed Performance and Future Challenges